Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications

Background: Pharmacogenomic testing, specifically for pharmacokinetic (PK) and pharmacodynamic (PD) genetic variation, may contribute to a better understanding of baseline genetic differences in patients seeking treatment for depression, which may further impact clinical antidepressant treatment rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Veldic, Marin, Ahmed, Ahmed T., Blacker, Caren J., Geske, Jennifer R., Biernacka, Joanna M., Borreggine, Kristin L., Moore, Katherine M., Prieto, Miguel L., Vande Voort, Jennifer L., Croarkin, Paul E., Hoberg, Astrid A., Kung, Simon, Alarcon, Renato D., Keeth, Nicola, Singh, Balwinder, Bobo, William V., Frye, Mark A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6389687/
https://www.ncbi.nlm.nih.gov/pubmed/30837869
http://dx.doi.org/10.3389/fphar.2019.00083

Ejemplares similares

Ejemplares similares